Sunshine Biopharma plans up to $4 million at-the-market share sale via Aegis Capital
SBFM•At-the-market equity program
Sunshine Biopharma set up an at-the-market equity program to sell up to $4 million of common stock over time on Nasdaq.
Aegis Capital will act as exclusive sales agent, earning a 3% commission on gross proceeds.
The program gives the company flexibility to raise capital opportunistically, with no obligation to sell any shares.
